Cancer Research

Cancer Research Program

Research Investigator

Isoken Koko, MD, Hematology-Oncology
Phone: (708) 763-2700

Interim Director of Cancer Research/Research Nurse

Julie Koch, RN, BSN, OCN, CCRP
Phone: (708) 763-2707
Cell: (708) 238-7574
Email: [email protected]

Regulatory Affairs

Ashley Bolden
Phone: (708) 763-2707
Email: [email protected]

Active Protocols by Disease Site

Breast

Adjuvant

Gilead Ascent-05

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy. NCT05633654

NRG-BR009

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) NCT05879926

Prevention

Alliance A191901

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions / Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy. NCT04379570

SWOG 2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN). NCT05568472

Treatment-First Line Metastatic

SWOG 1703

Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer. NCT03723928

Colon/Rectal

Prevention

Alliance A221805

Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study. NCT04137107

Multiple Sites

Repository

Alliance A151804

ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS. NCT04242095

SWOG 2013

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors. NCT04871542

Supportive

Alliance 222004

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients. NCT04939090